As of 2025-03-17, the Relative Valuation of Neovacs SA (ALNEV.PA) is (2,622.75) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.06 EUR, the upside of Neovacs SA based on Relative Valuation is -4658620.6%.
The range of the Relative Valuation is (1,922.25) - (3,279.91) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 25.9x | 20.2x |
| Forward P/E multiples | 14.4x - 25.0x | 19.7x |
| Fair Price | (1,922.25) - (3,279.91) | (2,622.75) |
| Upside | -3414405.0% - -5825874.4% | -4658620.6% |
| Date | P/E |
| 2025-03-04 | -0.00 |
| 2025-03-03 | -0.00 |
| 2025-02-28 | -0.00 |
| 2025-02-27 | -0.00 |
| 2025-02-26 | -0.00 |
| 2025-02-25 | -0.00 |
| 2025-02-24 | -0.00 |
| 2025-02-21 | -0.00 |
| 2025-02-20 | -0.00 |
| 2025-02-19 | -0.00 |
| 2025-02-18 | -0.00 |
| 2025-02-17 | -0.00 |
| 2025-02-14 | -0.00 |
| 2025-02-13 | -0.00 |
| 2025-02-12 | -0.00 |
| 2025-02-11 | -0.00 |
| 2025-02-10 | -0.00 |
| 2025-02-07 | -0.00 |
| 2025-02-06 | -0.00 |
| 2025-02-05 | -0.00 |
| 2025-02-04 | -0.00 |
| 2025-02-03 | -0.00 |
| 2025-01-31 | -0.00 |
| 2025-01-30 | -0.00 |
| 2025-01-29 | -0.00 |
| 2025-01-28 | -0.00 |
| 2025-01-27 | -0.00 |
| 2025-01-24 | -0.00 |
| 2025-01-23 | -0.00 |
| 2025-01-22 | -0.00 |
| 2025-01-21 | -0.00 |
| 2025-01-20 | -0.01 |
| 2025-01-17 | -0.01 |
| 2025-01-16 | -0.01 |
| 2025-01-15 | -0.01 |
| 2025-01-14 | -0.01 |
| 2025-01-13 | -0.01 |
| 2025-01-10 | -0.01 |
| 2025-01-09 | -0.01 |
| 2025-01-08 | -0.01 |
| 2025-01-07 | -0.01 |
| 2025-01-06 | -0.01 |
| 2025-01-03 | -0.01 |
| 2025-01-02 | -0.01 |
| 2024-12-31 | -0.01 |
| 2024-12-30 | -0.01 |
| 2024-12-27 | -0.01 |
| 2024-12-24 | -0.01 |
| 2024-12-23 | -0.01 |
| 2024-12-20 | -0.01 |